share_log

Bruker Corp | 10-Q: Q2 2024 Earnings Report

Bruker Corp | 10-Q: Q2 2024 Earnings Report

布魯克 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/10 04:43

Moomoo AI 已提取核心訊息

Bruker Corporation reported Q2 2024 revenue of $800.7 million, up 17.4% from $681.9 million in Q2 2023, driven by 11.1% growth from acquisitions and 7.4% organic growth. However, net income declined to $7.6 million from $57.1 million last year, primarily due to acquisition-related expenses and higher interest costs.Operating income decreased 44.2% to $48.1 million, with operating margin falling to 6.0% from 12.6%, impacted by integration costs from recent acquisitions of NanoString, ELITech, and Chemspeed. Gross profit margin declined to 48.0% from 49.9%, while selling, general and administrative expenses increased to 27.6% of revenue from 26.1%.The company completed several strategic acquisitions, including NanoString Technologies for $392.6 million, ELITechGroup for $951.9 million, and Chemspeed Technologies for $175.4 million. Bruker also raised $403 million through a public offering of 6 million shares and maintained strong liquidity with $169.7 million in cash and a $900 million credit facility.
Bruker Corporation reported Q2 2024 revenue of $800.7 million, up 17.4% from $681.9 million in Q2 2023, driven by 11.1% growth from acquisitions and 7.4% organic growth. However, net income declined to $7.6 million from $57.1 million last year, primarily due to acquisition-related expenses and higher interest costs.Operating income decreased 44.2% to $48.1 million, with operating margin falling to 6.0% from 12.6%, impacted by integration costs from recent acquisitions of NanoString, ELITech, and Chemspeed. Gross profit margin declined to 48.0% from 49.9%, while selling, general and administrative expenses increased to 27.6% of revenue from 26.1%.The company completed several strategic acquisitions, including NanoString Technologies for $392.6 million, ELITechGroup for $951.9 million, and Chemspeed Technologies for $175.4 million. Bruker also raised $403 million through a public offering of 6 million shares and maintained strong liquidity with $169.7 million in cash and a $900 million credit facility.
布魯克公司報告2024年第二季度營業收入爲80070萬美元，比2023年第二季度的68190萬美元增長17.4%，這主要得益於收購帶來的11.1%的增長和7.4%的內生增長。然而，凈利潤從去年的5710萬美元下降到760萬美元，主要是由於與收購相關的費用和較高的利息成本。營業收入下降了44.2%，降至4810萬美元，營業利潤率從12.6%降至6.0%，受到了近期收購NanoString、ELITech和Chemspeed的整合成本的影響。毛利潤率從49.9%降至48.0%，而銷售、一般和行政費用的比例則從26.1%增加到27.6%。該公司完成了幾項戰略收購，包括以39260萬美元收購NanoS...展開全部
布魯克公司報告2024年第二季度營業收入爲80070萬美元，比2023年第二季度的68190萬美元增長17.4%，這主要得益於收購帶來的11.1%的增長和7.4%的內生增長。然而，凈利潤從去年的5710萬美元下降到760萬美元，主要是由於與收購相關的費用和較高的利息成本。營業收入下降了44.2%，降至4810萬美元，營業利潤率從12.6%降至6.0%，受到了近期收購NanoString、ELITech和Chemspeed的整合成本的影響。毛利潤率從49.9%降至48.0%，而銷售、一般和行政費用的比例則從26.1%增加到27.6%。該公司完成了幾項戰略收購，包括以39260萬美元收購NanoString Technologies、以95190萬美元收購ELITechGroup，以及以17540萬美元收購Chemspeed Technologies。布魯克還通過公開發行600萬股籌集了40300萬美元，並保持了良好的流動性，擁有16970萬美元現金和90000萬美元的信用額度。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Allurion Technologies
    ALUR
    -- 8.690
    PAVmed
    PAVMZ
    -- 0.0199
    Senseonics
    SENS
    -- 1.1300
    Bluejay Diagnostics
    BJDX
    -- 4.4400
    Perspective Therapeutics
    CATX
    -- 4.0100
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    中美談話新契機，通脹不再？
    🎙️討論： 1. 特朗普上台後，對華政策如何影響中國資產？ 2. 美股市場通脹風險下降，哪些板塊受益？ 展开
    中國將在明年採取 “適度寬鬆” 的貨幣政策，這是自2011年以來首次轉向寬鬆